Free Oncology CME

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a disease in which leukemic cells accumulate in the peripheral blood, bone marrow, and lymphatic tissue. Elderly patients comprise the vast majority of those diagnosed with CLL with a mean patient age of 72 years. There are over 23,000 cases in the U.S. per year, with an annual mortality rate in excess of 4,400. CLL may have an indolent disease course and go undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy (the most common), night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by cytogenetic abnormalities and earlier progression of disease. Both the presentation and progression of CLL vary between patients, although patients with very-high-risk disease have a median survival of 19 months and a five-year overall survival of less than 24%.

Hear from a panel of clinicians from community practices about their experiences, including the challenges and successes, with integrating B-cell maturation antigen (BCMA)-directed bispecific antibodies into their practices. Explore patient management strategies for bispecific antibodies, from starting treatment at a community center to providing long-term care after treatment initiation at either a community or tertiary center.

In this MedX activity, Robert Haddad, MD, explores the latest clinical data for emerging novel therapies for recurrent/metastatic head and neck squamous cell carcinoma with an emphasis on results presented at ESMO 2025.

In this online, self-learning activity:

Lung cancer is the leading cause of cancer-related death in the United States, with more than 236,000 new cases diagnosed and over 124,000 deaths annually. The most common type of lung cancer, non–small cell lung cancer (NSCLC), accounts for about 85% of cases and has seen steady declines in mortality over the past several years as improvements have been made in diagnosis, staging, and treatment. In contrast, outcomes for the less prevalent small cell lung cancer (SCLC), which is neuroendocrine in nature and accounts for about 14% of all lung cancer cases, have remained poor in recent years despite improvement in those for NSCLC.

In this online, self-learning activity:

Polycythemia vera (PV) is an uncommon hematologic malignancy belonging to BCR-ABL1-negative myeloproliferative neoplasms (MPNs), characterized by activating mutations in JAK2 that cause the proliferation of malignant hematopoietic stem and progenitor cells. PV is characterized by erythrocytosis, thrombocytosis, leukocytosis, and splenomegaly, with approximately 50% of patients presenting symptoms such as fatigue, headache, visual disturbances, and pruritus at diagnosis. Others may be asymptomatic and diagnosed incidentally through blood tests, and as the disease progresses, individuals often experience worsening symptoms along with new ones, including early satiety and inactivity. Approximately 148,000 individuals in the United States have PV; the annual incidence of PV ranges from 0.01 to 2.61 per 100,000 individuals, while its prevalence varies from 45 to 57 per 100,000. Primarily affecting older individuals, PV has an overall median age of 61 years, with less than 10% of cases occurring in those under 40 years old.

Faculty discusses the prevention and management of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and infections in patients with relapsed/refractory multiple myeloma treated with BCMA-directed bispecific antibodies.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Discover how communities of practice are expanding access to bispecific antibodies, as faculty share practical guidance on starting these therapies in community settings and smoothly transitioning patients from academic centers to local care.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

Patient advocate and HealthTree Foundation CEO Jenny Ahlstrom shares fresh survey insights into the physical, emotional, and social quality-of-life experiences of patients treated with bispecific antibodies, while spotlighting key educational, financial, and community resources designed to support them.

This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.

This CME activity reviews the efficacy and safety of available B-cell maturation antigen (BCMA)-directed bispecific antibodies for multiple myeloma and explores the latest clinical data on their use in earlier lines of therapy and in emerging combination regimens.

This CME activity reviews various barriers to accessing B-cell maturation antigen (BCMA)-directed therapies that patients with multiple myeloma may experience. The impact of these barriers on health outcomes is discussed, along with strategies and policy solutions to help overcome them.

This CME activity explores the latest clinical data and provides guidance on when to consider treatment with available B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs), chimeric antigen receptor (CAR) T-cell therapy, or antibody-drug conjugate (ADC) therapy for patients with relapsed/refractory multiple myeloma (RRMM) based on patient-, disease-, and treatment-related factors.